S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Fusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:FUSN)

$5.74
+0.34 (+6.30%)
(As of 12/7/2023 ET)
Compare
Today's Range
$5.27
$5.85
50-Day Range
$2.48
$5.74
52-Week Range
$2.30
$5.85
Volume
409,629 shs
Average Volume
182,544 shs
Market Capitalization
$415.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.20

Fusion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.5% Upside
$12.20 Price Target
Short Interest
Healthy
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of Fusion Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.47) to ($1.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

152nd out of 960 stocks

Biological Products, Except Diagnostic Industry

16th out of 141 stocks


FUSN stock logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

FUSN Stock Price History

FUSN Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Fusion Pharmaceuticals Inc Ordinary Shares FUSN
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
10 Oversold Penny Stocks To Buy
Fusion Pharmaceuticals (FUSN) Gets a Buy from Truist Financial
See More Headlines
Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FUSN
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.20
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+112.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-87,610,000.00
Net Margins
-4,136.55%
Pretax Margin
-4,175.00%

Debt

Sales & Book Value

Annual Sales
$2.21 million
Book Value
$3.62 per share

Miscellaneous

Free Float
66,795,000
Market Cap
$415.61 million
Optionable
Not Optionable
Beta
-1.10
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. John F. Valliant Ph.D. (Age 53)
    Founder, CEO & Director
    Comp: $864.72k
  • Mr. John J. Crowley CPA (Age 49)
    Chief Financial Officer
    Comp: $670.1k
  • Dr. Eric Burak Ph.D. (Age 58)
    Chief Technology Officer
    Comp: $638.04k
  • Mr. Mohit Rawat (Age 43)
    President & Chief Business Officer
  • Dr. Christopher Paul Leamon Ph.D. (Age 57)
    Chief Scientific Officer
  • Ms. Amanda Cray
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Maria D. Stahl (Age 52)
    Chief Legal Officer
  • Mr. Eric S. Hoffman Ph.D. (Age 53)
    Senior Vice President of Business Development
  • Dr. Cara Ferreira Ph.D.
    Chief of Staff
  • Dr. Joanne Schindler
    Executive Vice President of Medical Director & Clinical Development














FUSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Fusion Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FUSN shares.
View FUSN analyst ratings
or view top-rated stocks.

What is Fusion Pharmaceuticals' stock price target for 2024?

6 analysts have issued twelve-month target prices for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $10.00 to $13.00. On average, they expect the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price.
View analysts price targets for FUSN
or view top-rated stocks among Wall Street analysts.

How have FUSN shares performed in 2023?

Fusion Pharmaceuticals' stock was trading at $3.15 at the beginning of 2023. Since then, FUSN stock has increased by 82.2% and is now trading at $5.74.
View the best growth stocks for 2023 here
.

Are investors shorting Fusion Pharmaceuticals?

Fusion Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 92,200 shares, a decline of 35.9% from the October 31st total of 143,900 shares. Based on an average daily volume of 180,200 shares, the days-to-cover ratio is currently 0.5 days.
View Fusion Pharmaceuticals' Short Interest
.

When is Fusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our FUSN earnings forecast
.

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 7th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $0.41 million. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.42% and a negative net margin of 4,136.55%.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (14.75%), Avidity Partners Management LP (7.98%), FMR LLC (5.77%), Eagle Health Investments LP (0.84%), Forefront Analytics LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adams Street Partners Llc, John Valliant and Steven Gannon.
View institutional ownership trends
.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:FUSN) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -